Works matching DE "HER2 positive breast cancer"
Results: 906
Human Blood Serum Counteracts EGFR/HER2-Targeted Drug Lapatinib Impact on Squamous Carcinoma SK-BR-3 Cell Growth and Gene Expression.
- Published in:
- Biochemistry (00062979), 2024, v. 89, n. 3, p. 487, doi. 10.1134/S000629792403009X
- By:
- Publication type:
- Article
Tailoring the Treatment of Early-stage HER2-positive Breast Cancer: One Size Does Not Fit All.
- Published in:
- touchREVIEWS in Oncology & Haematology, 2023, v. 19, n. 1, p. 11, doi. 10.17925/OHR.2023.19.1.11
- By:
- Publication type:
- Article
Trastuzumab Deruxtecan for the Treatment of HER2-positive Breast Cancer.
- Published in:
- touchREVIEWS in Oncology & Haematology, 2023, v. 19, n. 1, p. 6, doi. 10.17925/OHR.2023.19.1.6
- By:
- Publication type:
- Article
An update on metastatic breast cancer New targeted therapies.
- Published in:
- Medicine Today, 2024, v. 25, n. 8, p. 51
- By:
- Publication type:
- Article
Early-stage breast cancer: Update on management.
- Published in:
- Medicine Today, 2024, v. 25, n. 4, p. 45
- By:
- Publication type:
- Article
Therapeutic management challenges in a polyallergic HER2-positive breast cancer patient.
- Published in:
- Oncolog-Hematolog, 2024, v. 69, n. 4, p. 46
- By:
- Publication type:
- Article
Trastuzumab deruxtecan (T-DXd) – a single-center real-world data experience in HER2-positive patients.
- Published in:
- Oncolog-Hematolog, 2024, v. 69, n. 4, p. 35
- By:
- Publication type:
- Article
Surprising results in the management of HER2-positive, hormone receptor-positive breast cancer progressing to metastatic disease.
- Published in:
- Oncolog-Hematolog, 2024, v. 69, n. 4, p. 31
- By:
- Publication type:
- Article
Improved Survival of a HER2-Positive Metastatic Breast Cancer Patient Following a Personalized Peptide Immunization.
- Published in:
- Vaccines, 2023, v. 11, n. 6, p. 1023, doi. 10.3390/vaccines11061023
- By:
- Publication type:
- Article
Hypofunction of macrophage chemotaxis contributes to defective efficacy of herceptin in HER2-positive breast cancer patients.
- Published in:
- Molecular & Cellular Oncology, 2024, v. 11, n. 1, p. 1, doi. 10.1080/23723556.2024.2309715
- By:
- Publication type:
- Article
多柔比星脂质体在晚期乳腺癌治疗的疗效和安全性分析.
- Published in:
- Progress in Modern Biomedicine, 2024, v. 24, n. 19, p. 3781, doi. 10.13241/j.cnki.pmb.2024.19.048
- By:
- Publication type:
- Article
Efficacy and safety of PI3K/Akt/mTOR inhibitors combined with trastuzumab therapy for HER2-positive breast cancer: a meta-analysis.
- Published in:
- European Review for Medical & Pharmacological Sciences, 2022, v. 26, n. 20, p. 7667
- By:
- Publication type:
- Article
Comparing trastuzumab-related cardiotoxicity between elderly and younger patients with breast cancer: a prospective cohort study.
- Published in:
- European Review for Medical & Pharmacological Sciences, 2021, v. 25, n. 24, p. 7643
- By:
- Publication type:
- Article
Financial toxicity of radiotherapy for multiple brain metastases: Will it get worse or better?
- Published in:
- Neuro-Oncology Practice, 2023, v. 10, n. 4, p. 318, doi. 10.1093/nop/npad018
- By:
- Publication type:
- Article
Echocardiographic Assessment of Ventricular Cardiomyopathy in Patients with Breast Cancer under Trastuzumab Chemotherapy.
- Published in:
- Journal of Cardio-Thoracic Medicine, 2024, v. 12, n. 2, p. 1329, doi. 10.22038/jctm.2024.79819.1458
- By:
- Publication type:
- Article
Development and evaluation of <sup>89</sup>Zr-trastuzumab for clinical applications.
- Published in:
- Asia Oceania Journal of Nuclear Medicine & Biology, 2023, v. 11, n. 2, p. 135, doi. 10.22038/AOJNMB.2022.68093.1471
- By:
- Publication type:
- Article
Characterization of Loss-of-Imprinting in Breast Cancer at the Cellular Level by Integrating Single-Cell Full-Length Transcriptome with Bulk RNA-Seq Data.
- Published in:
- Biomolecules (2218-273X), 2024, v. 14, n. 12, p. 1598, doi. 10.3390/biom14121598
- By:
- Publication type:
- Article
Distinct discrepancy in breast cancer organoids recapitulation among molecular subtypes revealed by single‐cell transcriptomes analysis.
- Published in:
- Clinical & Translational Medicine, 2024, v. 14, n. 9, p. 1, doi. 10.1002/ctm2.70023
- By:
- Publication type:
- Article
Efficacy and safety of pyrotinib combined with albumin‐bound paclitaxel as first‐line treatment for HER2‐positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single‐arm, phase 2 prospective clinical trial
- Published in:
- Clinical & Translational Medicine, 2024, v. 14, n. 5, p. 1, doi. 10.1002/ctm2.1687
- By:
- Publication type:
- Article
Large‐scale genomic sequencing reveals adaptive opportunity of targeting mutated‐PI3Kα in early and advanced HER2‐positive breast cancer.
- Published in:
- Clinical & Translational Medicine, 2021, v. 11, n. 11, p. 1, doi. 10.1002/ctm2.589
- By:
- Publication type:
- Article
A historical controlled study of domestic trastuzumab and pertuzumab in combination with docetaxel for the neoadjuvant treatment of early HER2-positive breast cancer.
- Published in:
- Frontiers in Oncology, 2024, p. 01, doi. 10.3389/fonc.2024.1281643
- By:
- Publication type:
- Article
Bilateral inflammatory recurrence of HER-2 positive breast cancer: a unique case report and literature review.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1276637
- By:
- Publication type:
- Article
Long-term response to sequential anti-HER2 therapies including trastuzumabderuxtecan in a patient with HER2-positive metastatic breast cancer with leptomeningeal metastases: a case report and review of the literature.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2023.1210873
- By:
- Publication type:
- Article
Triple-negative and Her2-positive breast cancer in women aged 70 and over: prognostic impact of age according to treatment.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1287253
- By:
- Publication type:
- Article
Disitamab Vedotin (RC48) for HER2-positive advanced breast cancer: a case report and literature review.
- Published in:
- Frontiers in Oncology, 2023, p. 1
- By:
- Publication type:
- Article
Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1264861
- By:
- Publication type:
- Article
Economic evaluation of third-line neratinib plus capecitabine versus lapatinib plus capecitabine with HER2+ metastatic breast cancer.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1221969
- By:
- Publication type:
- Article
The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1108242
- By:
- Publication type:
- Article
Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1177681
- By:
- Publication type:
- Article
Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer: a real-world retrospective study in China.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1136380
- By:
- Publication type:
- Article
Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trial.
- Published in:
- Frontiers in Oncology, 2023, p. 01, doi. 10.3389/fonc.2023.1139347
- By:
- Publication type:
- Article
Immunotherapy for HER-2 positive breast cancer.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.1097983
- By:
- Publication type:
- Article
The efficacy and safety of epirubicin and cyclophosphamide combined with pyrotinib in neoadjuvant treatment for HER2-positive breast cancer: A realworld study.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.1041111
- By:
- Publication type:
- Article
Review of the status of neoadjuvant therapy in HER2-positive breast cancer.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.1066007
- By:
- Publication type:
- Article
Matrix metalloproteinases as therapeutic targets in breast cancer.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2022.1108695
- By:
- Publication type:
- Article
HER2-positive metastatic breast cancer with brain metastases responds favorably to pyrotinib and trastuzumab-based treatment: A case report and literature review.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2022.980635
- By:
- Publication type:
- Article
Analysis of the clinicopathological characteristics and prognosis of triple-positive breast cancer and HER2-positive breast cancer--A retrospective study.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 01, doi. 10.3389/fonc.2022.999894
- By:
- Publication type:
- Article
The role of radiotherapy in HER2+ early-stage breast cancer patients after breast-conserving surgery.
- Published in:
- Frontiers in Oncology, 2023, v. 12, p. 1, doi. 10.3389/fonc.2022.903001
- By:
- Publication type:
- Article
Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirus.
- Published in:
- Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1181014
- By:
- Publication type:
- Article
Focusing on NK cells and ADCC: A promising immunotherapy approach in targeted therapy for HER2-positive breast cancer.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 01, doi. 10.3389/fimmu.2022.1083462
- By:
- Publication type:
- Article
Comparison between talazoparib and conventional chemotherapy in the treatment of HER2-positive breast cancer patients: A retrospective study.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 01, doi. 10.3389/fimmu.2022.901636
- By:
- Publication type:
- Article
Determining the Optimal (Neo)Adjuvant Regimen for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Regarding Survival Outcome: A Network Meta-Analysis.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.919369
- By:
- Publication type:
- Article
Value of <sup>18</sup>F-FDG PET/CT for predicting axillary pathologic complete response following neoadjuvant systemic therapy in breast cancer patients: emphasis on breast cancer subtype.
- Published in:
- EJNMMI Research, 2021, v. 11, n. 1, p. 1, doi. 10.1186/s13550-021-00861-z
- By:
- Publication type:
- Article
Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer.
- Published in:
- Lung Cancer: Targets & Therapy, 2021, v. 12, p. 103, doi. 10.2147/LCTT.S307324
- By:
- Publication type:
- Article
Evolving standards of care and new challenges in the management of HER2‐positive breast cancer.
- Published in:
- CA: A Cancer Journal for Clinicians, 2020, v. 70, n. 5, p. 355, doi. 10.3322/caac.21634
- By:
- Publication type:
- Article
Transgenic overexpression of the miR‐200b/200a/429 cluster prevents mammary tumor initiation in Neu/Erbb2 transgenic mice.
- Published in:
- International Journal of Cancer, 2025, v. 156, n. 5, p. 993, doi. 10.1002/ijc.35211
- By:
- Publication type:
- Article
Real‐world treatment patterns and outcomes of pyrotinib‐based therapy in patients with HER2‐positive advanced breast cancer (PRETTY): A nationwide, prospective, observational study.
- Published in:
- International Journal of Cancer, 2023, v. 153, n. 10, p. 1809, doi. 10.1002/ijc.34676
- By:
- Publication type:
- Article
Nanoparticle drug delivery to target breast cancer brain metastasis: Current and future trends.
- Published in:
- International Journal of Cancer, 2023, v. 153, n. 6, p. 1118, doi. 10.1002/ijc.34542
- By:
- Publication type:
- Article
Pertuzumab study in the neoadjuvant setting for HER2‐positive nonmetastatic breast cancer in Australia (PeRSIA).
- Published in:
- International Journal of Cancer, 2023, v. 152, n. 2, p. 267, doi. 10.1002/ijc.34245
- By:
- Publication type:
- Article
Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: Real‐world data from a multicentric European cohort.
- Published in:
- International Journal of Cancer, 2022, v. 151, n. 8, p. 1355, doi. 10.1002/ijc.34135
- By:
- Publication type:
- Article